Jilin Yatai Group Co Ltd
SSE:600881
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (34.5), the stock would be worth ¥1.06 (29% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 48.4 | ¥1.48 |
0%
|
| 3-Year Average | 34.5 | ¥1.06 |
-29%
|
| 5-Year Average | 19.4 | ¥0.59 |
-60%
|
| Industry Average | 15.7 | ¥0.48 |
-68%
|
| Country Average | 20.8 | ¥0.64 |
-57%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Jilin Yatai Group Co Ltd
SSE:600881
|
4.8B CNY | 48.4 | -1.9 | |
| IE |
C
|
CRH PLC
NYSE:CRH
|
78B USD | 16.2 | 20.8 | |
| CH |
|
Holcim AG
SIX:HOLN
|
40.3B CHF | 15.4 | 3.1 | |
| DE |
|
HeidelbergCement AG
XETRA:HEI
|
33.1B EUR | 11.5 | 17.1 | |
| US |
|
Vulcan Materials Co
NYSE:VMC
|
38B USD | 23 | 35.3 | |
| IN |
|
UltraTech Cement Ltd
NSE:ULTRACEMCO
|
3.5T INR | 25.6 | 48.2 | |
| US |
|
Martin Marietta Materials Inc
NYSE:MLM
|
36.8B USD | 23.5 | 32.3 | |
| US |
A
|
Amrize AG
SIX:AMRZ
|
24.7B CHF | 15.7 | 26.5 | |
| DE |
H
|
Heidelberg Materials AG
XMUN:HEI
|
21.7B EUR | 7.9 | 11.2 | |
| IN |
|
Grasim Industries Ltd
NSE:GRASIM
|
1.9T INR | -20.8 | 44.8 | |
| CN |
|
China Jushi Co Ltd
SSE:600176
|
132.7B CNY | 34.1 | 40.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.5 |
| Median | 20.8 |
| 70th Percentile | 39.2 |
| Max | 266 666.7 |
Other Multiples
Jilin Yatai Group Co Ltd
Glance View
Jilin Yatai Group Co., Ltd. stands as a multifaceted conglomerate, deeply entrenched in the economic landscape of China with a robust emphasis on construction materials, real estate, and pharmaceuticals. Founded in the early 1990s, the company steadily carved its niche in the industrial sector, beginning with the production of cement—a pivotal material for China's infrastructure boom. Over the years, Jilin Yatai expanded its portfolio, strategically diversifying into industries that not only complemented its core business but also capitalized on emerging market trends. The real estate division evolved into a significant revenue driver, leveraging the construction material supply chain, which allowed it to develop residential and commercial properties efficiently. This vertical integration enabled the company to maintain a competitive edge, managing cost structures while ensuring quality and reliability in project delivery. In a bid to further consolidate its position and mitigate risks inherent in the cyclical nature of construction and real estate, Jilin Yatai ventured into the pharmaceutical sector. This bold move introduced a new pillar of growth, aimed at capitalizing on the rising demand for healthcare products and services in China. The company's pharmaceutical arm focuses on the development, manufacturing, and distribution of various medicinal products, stretching its market influence to encompass both domestic and international arenas. By adopting a strategy of diversification that effectively balances high-growth industries, Jilin Yatai has developed a multifaceted approach to revenue generation. This approach not only underpins its sustained financial health but also allows it to remain adaptable and resilient in the face of economic fluctuations.